全文获取类型
收费全文 | 818篇 |
免费 | 66篇 |
国内免费 | 76篇 |
出版年
2023年 | 8篇 |
2022年 | 17篇 |
2021年 | 22篇 |
2020年 | 23篇 |
2019年 | 28篇 |
2018年 | 22篇 |
2017年 | 18篇 |
2016年 | 24篇 |
2015年 | 30篇 |
2014年 | 48篇 |
2013年 | 66篇 |
2012年 | 22篇 |
2011年 | 32篇 |
2010年 | 27篇 |
2009年 | 48篇 |
2008年 | 51篇 |
2007年 | 49篇 |
2006年 | 58篇 |
2005年 | 52篇 |
2004年 | 38篇 |
2003年 | 45篇 |
2002年 | 26篇 |
2001年 | 28篇 |
2000年 | 16篇 |
1999年 | 28篇 |
1998年 | 22篇 |
1997年 | 21篇 |
1996年 | 10篇 |
1995年 | 15篇 |
1994年 | 11篇 |
1993年 | 7篇 |
1992年 | 18篇 |
1991年 | 8篇 |
1990年 | 7篇 |
1989年 | 2篇 |
1988年 | 6篇 |
1985年 | 4篇 |
1983年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
排序方式: 共有960条查询结果,搜索用时 921 毫秒
141.
Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients
Valeska Hofmeister-Mueller Claudia S. Vetter-Kauczok Ramona Ullrich Katharina Meder Eugene Lukanidin Eva-Bettina Broecker Per thor Straten Mads Hald Andersen David Schrama Juergen C. Becker 《Cancer immunology, immunotherapy : CII》2009,58(8):1265-1273
S100A4 (metastasin 1) belongs to the S100 family of Ca2+ binding proteins. While not present in most differentiated adult tissues, S100A4 is upregulated in the micromilieu of tumors.
It is primarily expressed by tumor-associated macrophages, fibroblasts, and tumor endothelial cells. Due to its strong induction
in tumors S100A4 is a promising target for cancer immunotherapy. By reverse immunology, using epitope prediction programs,
we identified 3 HLA-A1-restricted peptide epitopes (S100A4 A1-1, A1-2, and A1-3) which are subject to human T cell responses
as detected in peripheral blood of melanoma patients by means of IFN-γ ELISPOT and cytotoxicity assays. In addition, IFN-γ
responses to S100A4 A1-2 can not only be induced by stimulation of T cells with peptide-loaded DC but also by stimulation
with S100A4 protein-loaded DC, indicating that this epitope is indeed generated by processing of the endogenously expressed
protein. In addition, S100A4 A1-2 reactive T cells demonstrate lysis of HLA-A1+ fibroblasts in comparison to HLA-A1− fibroblasts. In summary, this HLA-A1-restricted peptide epitope is a candidate for immunotherapeutical approaches targeting
S100A4-expressing cells in the tumor stroma. 相似文献
142.
Wang X Santin AD Bellone S Gupta S Nakagawa M 《Cancer immunology, immunotherapy : CII》2009,58(2):309-308
Previously, safety and immunogenicity of human papillomavirus type 16 (HPV16) or 18 E7-pulsed dendritic cells (DC) vaccinations
were demonstrated in a dose-escalation Phase I clinical trial which enrolled ten patients diagnosed with stage IB or IIA cervical
cancer (nine HPV 16-positive, one HPV 18-positive). The goal of the study was to define the T-cell epitopes of HPV 16 or 18
E7 protein in these patients in order to develop new strategies for treating HPV-associated malignancies. This was accomplished
through establishing T-cell lines by stimulating peripheral blood mononuclear cells with autologous mature DC pulsed with
the HPV 16 or 18 E7 protein, examining the T-cell responses using ELISPOT assays, and isolating E7-specific T-cell clones
based on IFN-γ secretion. Then, the epitope was characterized in terms of its core sequence and the restriction element. Twelve
T-cell lines from eight subjects (seven HPV 16-positive, one HPV 18-positive) were evaluated. Positive T-cell responses were
demonstrated in four subjects (all HPV 16-positive). All four were positive for the HPV 16 E7 46-70 (EPDRAHYNIVTFCCKCDSTLRLCVQ)
region. T-cell clones specific for the E7 47–70 region were isolated from one of the subjects. Further analyses revealed a
novel, naturally processed, CD4 T-cell epitope, E7 58–68 (CCKCDSTLRLC), restricted by the HLA-DR17 molecule.
This work was supported by the National Institutes of Health (R21CA094507).
An erratum to this article can be found at 相似文献
143.
Siaw‐Lin Chan Caroline J. Voskens Wei Lin Daniel G. Schindler Agnes Azimzadeh Lai‐Xi Wang Rodney J. Taylor Scott E. Strome Dan H. Schulze 《Journal of molecular recognition : JMR》2009,22(3):242-249
Antibody based manipulation of the CD137 (4‐1BB) co‐signaling pathway is an attractive option for the treatment of cancer and autoimmune disease. We developed a chimeric anti‐human CD137 monoclonal antibody (GG) and characterized its function. As a component of planned preclinical studies, we evaluated the binding of GG to activated peripheral blood mononuclear cells (PBMCs) from cynomolgus macaque and baboon against human. Interestingly, GG only recognized human CD137, while a commercial anti‐CD137 mAb (4B4‐1), recognized activated PBMCs from both human and non‐human primates (NHP). Subsequent analysis revealed that the amino acid sequence of CD137 is largely conserved between primate species (~95% identical), with the extracellular domain differing by only 9–10 amino acids. Based on these data, we generated mutant constructs in the extracellular domain, replacing NHP with human CD137 sequences, and identified 3 amino acids critical for GG binding. These residues are likely part of a conformational epitope, as a peptide spanning this region is unable to block mAb binding. These data demonstrate that subtle sequence variations of defined co‐stimulatory molecules amongst primate species can be employed as a strategy for mapping residues necessary for antibody binding to conformational epitopes. Copyright © 2009 John Wiley & Sons, Ltd. 相似文献
144.
Takuo Fujisawa Walter Sebald 《Biochemical and biophysical research communications》2009,385(2):215-219
The VWC domain of Chordin family proteins consists of subdomains SD1 and SD2. In previous experiments with VWC1 from CV-2 SD-1 was shown to be crucial for BMP interaction. Now the SD1 from VWC1 and VWC3 of Chordin and CHL2 were established to confer BMP affinity and specificity to these proteins also. In addition, these SD1 subdomains are mediating binding to Tsg. Mutational analysis revealed similar binding epitopes of the various SD1 proteins for BMP-2 and Tsg. Inhibitory activity of CHL2 in C2C12 cells is reduced by mutations in SD1 of VWC1 and even more of VWC3. These results together provide strong evidence that the SD1 subdomain module of about 40 residues represents the crucial binding partner for BMPs and Tsg in these Chordin family proteins and likely in other BMP-binding VWC domains also. 相似文献
145.
146.
The use of antigenicity scales based on physicochemical properties and the sliding window method in combination with an averaging algorithm and subsequent search for the maximum value is the classical method for B-cell epitope prediction. However, recent studies have demonstrated that the best classical methods provide a poor correlation with experimental data. We review both classical and novel algorithms and present our own implementation of the algorithms. The AAPPred software is available at http://www.bioinf.ru/aappred/. 相似文献
147.
UreB蛋白B细胞抗原表位快速筛选与鉴定 总被引:2,自引:0,他引:2
以幽门螺旋杆菌(Helicobacterpylori,Hp)主要抗原蛋白尿素酶B(ureaseB,UreB)为靶蛋白,建立一种新的B细胞抗原表位筛选与鉴定方法.运用Fmoc固相肽合成法合成11条HpUreB蛋白的单表位抗原肽片段,在其氨基端标记FITC荧光素,应用荧光偏振方法(fluorescencepolarization,FP)快速鉴定这些肽片段的抗原性,并通过FP法在大规模样品中快速筛选相应抗体滴度高、分布人群广的优势抗原表位肽.结果表明,合成的11条UreB蛋白线性抗原肽中,10条具有较强的抗原性,其中No.2、No.5和No.11抗原肽相应的特异性抗体在感染Hp的人群中分布较广,抗体滴度较高,为UreB的优势抗原表位肽.对抗原表位进行多参数综合分析与设计,通过FP技术快速鉴定抗原肽,并筛选优势抗原表位肽,对于疾病的抗原表位谱研究具有重要的意义,同时在疾病的诊断、分型及治疗中具有重要的应用前景. 相似文献
148.
【目的】对葡激酶的T和B细胞抗原表位重叠的关键氨基酸Arg77和Glu80进行定点突变以降低葡激酶的免疫原性。【方法】基于Arg77和Glu80的溶剂可及表面积设计葡激酶的突变体;突变体在大肠杆菌DH5α中进行表达。经过三步层析法纯化后,分析突变体的纤溶活性和免疫原性。【结果】免疫学实验提示,葡激酶导致Th2免疫反应;Glu80突变为丙氨酸和丝氨酸减少了溶剂可及表面积,同时去除了部分T和B细胞抗原表位;Arg77突变为天冬酰胺、谷氨酰胺和赖氨酸仅去除了部分T细胞抗原表位;6个组合突变体中,Sak(R77Q/E80A)和Sak(R77Q/E80S)有效去除了部分B和T细胞抗原表位,降低了葡激酶的免疫原性;Sak(R77Q/E80A)and Sak(R77Q/E80S)的纤溶活性和催化效率与r-Sak相当。 相似文献
149.
Jing H Na T Zhang W Wu G Liu C Peng JB 《Biochemical and biophysical research communications》2011,(4):979-984
With-no-lysine (K) kinase 4 (WNK4) is a protein serine/threonine kinase associated with a Mendelian form of hypertension. WNK4 is an integrative regulator of renal transport of Na+, K+, and Cl− as shown in Xenopus oocyte system. In addition, WNK4 enhances the surface expression of epithelial Ca2+ channel TRPV5, which plays a key role in the fine tuning of renal Ca2+ reabsorption. Variations in the magnitude of WNK4-mediated regulation on TRPV5 in Xenopus oocytes suggest additional cellular components with limited expression are required for the regulation. In this study, we identified the Na+/H+ exchanger regulating factor 2 (NHERF2) as a critical component for the positive regulation of TRPV5 by WNK4. NHERF2 augmented the positive effect of WNK4 on TRPV5, whereas its homolog NHERF1 had no effect when tested in the Xenopus oocyte system. The C-terminal PDZ binding motif of TRPV5 was required for the regulation by NHERF2. While NHERF2 interacted with TRPV5, no association between NHERF2 and WNK4 was detected using a GST pull-down assay. WNK4 increased the forward trafficking of TRPV5; however, it also caused an accelerated decline of the functional TRPV5 channels at later stage of co-expression. NHERF2 stabilized TRPV5 at the plasma membrane without interrupting the forward trafficking of TRPV5, thus prevented the decline of functional TRPV5 channel caused by WNK4 at later stage. The complementary and orderly regulations of WNK4 and NHERF2 allow TRPV5 functions at higher level for a longer period to maximize Ca2+ influx. 相似文献
150.
Although CD8+ cytotoxic T lymphocyte (CTL) epitope-based DNA vaccination is valuable experience on vaccine research but many attempts are still continued to achieve acceptable protective response. To study the role of full length antigen in CTL epitope immunization, we evaluated cellular immunity of diverse patterns of complete Herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) and the immunodominant CTL epitope (498–505) DNA injection in C57BL/6 mice. Optimal immune response was observed in the group immunized with the full length of gB in the first injection and CTL epitope in the second and third vaccination as assessed by lymphocyte proliferation assay (MTT), cytokine assay (ELISA) and CTL assay. B cell and spatially CD4+ T cell epitopes in full length protein might be important for appropriate priming of CTL immune response. These findings may have important implication for the improvement of CTL epitope based DNA vaccine against HSV and other pathogens. 相似文献